Clinical Outcomes of an New EDOF IOL (Isopure®)

Conditions: Lens Opacities, Cataract, Pseudophakia

Sex: All

Ages: 50 Years – N/A

Enrollment: 62

Sponsor: Kristof Vandekerckhove, MD, MBA

Location: Switzerland

Summary

Single-center, retrospective, open-label observational study aiming to evaluate visual outcomes and patient satisfaction after bilateral implantation of Isopure® EDOF-IOL with a mono-minovision target.

Eligibility Criteria

Inclusion Criteria:Male or female patients aged 50 years or older undergoing a routine cataract surgery and benefiting from bilateral IOL implantation with Isopure 1.2.3 IOL;Patient's willingness to participate in the study;Capacity to understand and sign an informed consent form and comply with examination procedures;Cataractous eyes with no vision-impacting comorbidity (estimated visual potential post-surgery 0.2 logMAR or better);Regular total corneal astigmatism ≤1.5 D (measured by topography method)Exclusion Criteria:Cooperation difficulties (distance from home, general health conditions, cognitive impairment);Subjects with diagnosed extra- or intraocular vision-affecting comorbidities (macular degeneration, glaucoma or other retinal or optic nerve disorders, previous ocular surgeries, amblyopia);Patients who previously benefitted from refractive surgery (PRK/LASIK) were included if no refractive surgery-related complications were noted (i.e: ectasia, corneal haze, dry eye);History or presence of macular edema;Perioperative complications;Congenital, uveitic, traumatic or surgically-complicated cataractRegular total corneal astigmatism >1.5 dioptres (measured by topography method)Irregular cornea, including keratotomy

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05704686). StuddyBuddy aggregates publicly available trial information.